|Videos|May 12, 2023
Managing Dry Eye Disease Before Cataract and Refractive Surgery
Experts discuss managing patients with overlapping eye diseases that require concurrent treatment, including before cataract and refractive surgery.
Advertisement
Episodes in this series
Advertisement
Related to this article
The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity
4
When to Switch Biologics in Severe Asthma, With Florence Schleich, MD, PhD
5